1. Reversal of atrophic body gastritis after H. pylori eradication at long-term follow-up
- Author
-
John Osborn, Edith Lahner, Emilio Di Giulio, Bruno Annibale, Emanuela Pilozzi, Cesare Bordi, Gianfranco Delle Fave, Vito D. Corleto, and Lucy Vannella
- Subjects
Adult ,Gastritis, Atrophic ,Male ,medicine.medical_specialty ,Adolescent ,intestinal metaplasia ,Gastroenterology ,Antibodies ,Helicobacter Infections ,Young Adult ,atrophic body gastritis ,h. pylori infection ,Atrophy ,Parietal Cells, Gastric ,Pepsinogen A ,Internal medicine ,Anemia, Pernicious ,Gastrins ,Pyloric Antrum ,medicine ,Humans ,Antrum ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Aged, 80 and over ,Metaplasia ,Helicobacter pylori ,Hepatology ,biology ,business.industry ,Intestinal metaplasia ,Retrospective cohort study ,Middle Aged ,bacterial infections and mycoses ,medicine.disease ,biology.organism_classification ,Intestines ,Cohort ,Regression Analysis ,Female ,Gastritis ,medicine.symptom ,business ,Follow-Up Studies ,Cohort study - Abstract
The effect of Helicobacter pylori treatment on the potential reversal of atrophic body gastritis (ABG) is controversial. Body atrophy reversal was evaluated in a cohort of H. pylori-negative and treated H. pylori-positive ABG patients.Observational long-term follow-up cohort study including 300 ABG patients with at least one follow-up gastroscopy with three biopsies from the antrum and three from the body performed no earlier than 1 year after diagnosis was included. H. pylori was diagnosed by Giemsa-stain and serology. H. pylori-positive patients (n = 192) were treated with bismuth-based triple regimen.After a mean follow-up of 5.2 years, body atrophy reversal was observed in 42/300 patients (14%). Body atrophy reversal occurred more frequently in patients treated for H. pylori than in H. pylori-negative ones (21.3% vs 0.9%, p0.00001) and was observed between 2 and 8 years after treatment in 52% of cases. Predictive factors for body atrophy reversal at Cox-regression analysis were mild atrophy (HR 2.14; 95% CI 1.12-4.1), moderate-severe inflammation (HR 5.3; 95% CI 1.64-17.3), and absence of intestinal metaplasia (HR 2.4; 95% CI 1.2-4.8).Body atrophy reversal was observed in about 20% of ABG patients treated for H. pylori infection, and about 50% of reversals occurred during long-term follow-up.
- Published
- 2011
- Full Text
- View/download PDF